1623 related articles for article (PubMed ID: 11419424)
1. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Cannon CP; Weintraub WS; Demopoulos LA; Vicari R; Frey MJ; Lakkis N; Neumann FJ; Robertson DH; DeLucca PT; DiBattiste PM; Gibson CM; Braunwald E;
N Engl J Med; 2001 Jun; 344(25):1879-87. PubMed ID: 11419424
[TBL] [Abstract][Full Text] [Related]
2. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E
Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697
[TBL] [Abstract][Full Text] [Related]
3. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
Huynh T; Theroux P; Snapinn S; Wan Y;
Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321
[TBL] [Abstract][Full Text] [Related]
4. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
Okmen E; Cakmak M; Tartan Z; Cam N
Heart Vessels; 2003 Jul; 18(3):117-22. PubMed ID: 12955426
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
[TBL] [Abstract][Full Text] [Related]
7. Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improves survival in non-ST-segment elevation acute coronary syndromes: a meta-analysis and review of the literature.
Bavry AA; Kumbhani DJ; Quiroz R; Ramchandani SR; Kenchaiah S; Antman EM
Am J Cardiol; 2004 Apr; 93(7):830-5. PubMed ID: 15050484
[TBL] [Abstract][Full Text] [Related]
8. Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results.
Dobrzycki S; Mezyński G; Kralisz P; Prokopczuk P; Nowak K; Kochman W; Zuk J; Bachórzewska-Gajewska H; Sawicki Z; Poniatowski B; Korecki J; Musiał WJ
Kardiol Pol; 2006 Aug; 64(8):793-9; discussion 800-1. PubMed ID: 16981054
[TBL] [Abstract][Full Text] [Related]
9. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Sabatine MS; Cannon CP; Gibson CM; López-Sendón JL; Montalescot G; Theroux P; Claeys MJ; Cools F; Hill KA; Skene AM; McCabe CH; Braunwald E;
N Engl J Med; 2005 Mar; 352(12):1179-89. PubMed ID: 15758000
[TBL] [Abstract][Full Text] [Related]
10. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial Infarction.
Cannon CP; Weintraub WS; Demopoulos LA; Robertson DH; Gormley GJ; Braunwald E
Am J Cardiol; 1998 Sep; 82(6):731-6. PubMed ID: 9761082
[TBL] [Abstract][Full Text] [Related]
11. Improved in-hospital outcomes in acute coronary syndromes (unstable angina/non-ST segment elevation myocardial infarction) despite similar TIMI risk scores.
Almeda FQ; Hendel RC; Nathan S; Meyer PM; Calvin JE; Klein LW
J Invasive Cardiol; 2003 Sep; 15(9):502-6. PubMed ID: 12947210
[TBL] [Abstract][Full Text] [Related]
12. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
Cohen M
J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
[TBL] [Abstract][Full Text] [Related]
13. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators
N Engl J Med; 1998 May; 338(21):1498-505. PubMed ID: 9599104
[TBL] [Abstract][Full Text] [Related]
14. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
Akkerhuis KM; Neuhaus KL; Wilcox RG; Vahanian A; Boland JL; Hoffmann J; Baardman T; Nehmiz G; Roth U; Klootwijk AP; Deckers JW; Simoons ML;
Eur Heart J; 2000 Dec; 21(24):2042-55. PubMed ID: 11102255
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet intervention in acute coronary syndrome.
Arora RR; Rai F
Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
[TBL] [Abstract][Full Text] [Related]
16. 5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome.
Damman P; Hirsch A; Windhausen F; Tijssen JG; de Winter RJ;
J Am Coll Cardiol; 2010 Mar; 55(9):858-64. PubMed ID: 20045278
[TBL] [Abstract][Full Text] [Related]
17. Use of glycoprotein IIb/IIIa inhibitors in invasively-treated patients with non-ST elevation acute coronary syndrome.
De Servi S; Mariani M; Vandoni P; Dellavalle A; Politi A; Poletti F; Bonizzoni E; Leoncinie M;
J Cardiovasc Med (Hagerstown); 2006 Mar; 7(3):159-65. PubMed ID: 16645379
[TBL] [Abstract][Full Text] [Related]
18. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
[TBL] [Abstract][Full Text] [Related]
19. Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: observations from the OPUS-TIMI 16 trial.
Cantor WJ; Goodman SG; Cannon CP; Murphy SA; Charlesworth A; Braunwauld E; Langer A
Am Heart J; 2005 Feb; 149(2):275-83. PubMed ID: 15846265
[TBL] [Abstract][Full Text] [Related]
20. Transfer with GP IIb/IIIa inhibitor tirofiban for primary percutaneous coronary intervention vs. on-site thrombolysis in patients with ST-elevation myocardial infarction (STEMI): a randomized open-label study for patients admitted to community hospitals.
Dobrzycki S; Kralisz P; Nowak K; Prokopczuk P; Kochman W; Korecki J; Poniatowski B; Zuk J; Sitniewska E; Bachorzewska-Gajewska H; Sienkiewicz J; Musial WJ
Eur Heart J; 2007 Oct; 28(20):2438-48. PubMed ID: 17884846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
